CN109316464B - 包含胰岛样细胞团的制剂 - Google Patents
包含胰岛样细胞团的制剂 Download PDFInfo
- Publication number
- CN109316464B CN109316464B CN201811295075.1A CN201811295075A CN109316464B CN 109316464 B CN109316464 B CN 109316464B CN 201811295075 A CN201811295075 A CN 201811295075A CN 109316464 B CN109316464 B CN 109316464B
- Authority
- CN
- China
- Prior art keywords
- islet
- chitosan
- collagen
- preparation
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims abstract description 47
- 210000000130 stem cell Anatomy 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 229920001661 Chitosan Polymers 0.000 claims description 25
- 102000008186 Collagen Human genes 0.000 claims description 21
- 108010035532 Collagen Proteins 0.000 claims description 21
- 229920001436 collagen Polymers 0.000 claims description 21
- 108020001507 fusion proteins Proteins 0.000 claims description 18
- 102000037865 fusion proteins Human genes 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 210000001185 bone marrow Anatomy 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- 239000008158 vegetable oil Substances 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 102000012422 Collagen Type I Human genes 0.000 claims description 2
- 108010022452 Collagen Type I Proteins 0.000 claims description 2
- 230000006196 deacetylation Effects 0.000 claims description 2
- 238000003381 deacetylation reaction Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 22
- 239000004005 microsphere Substances 0.000 abstract description 19
- 239000001963 growth medium Substances 0.000 abstract description 14
- 102000004877 Insulin Human genes 0.000 abstract description 11
- 108090001061 Insulin Proteins 0.000 abstract description 11
- 229940125396 insulin Drugs 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 6
- 239000002775 capsule Substances 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 239000003094 microcapsule Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 17
- 239000002609 medium Substances 0.000 description 14
- 241000700605 Viruses Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000003914 insulin secretion Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- UOFGSWVZMUXXIY-UHFFFAOYSA-N 1,5-Diphenyl-3-thiocarbazone Chemical compound C=1C=CC=CC=1N=NC(=S)NNC1=CC=CC=C1 UOFGSWVZMUXXIY-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 108010026333 seryl-proline Proteins 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 2
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 2
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- SKPQXOSVPKPXML-ULQDDVLXSA-N 2-[[(2s)-1-[(2s)-3-phenyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NCCC1)CC1=CC=CC=C1 SKPQXOSVPKPXML-ULQDDVLXSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- WXERCAHAIKMTKX-ZLUOBGJFSA-N Ala-Asp-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O WXERCAHAIKMTKX-ZLUOBGJFSA-N 0.000 description 1
- CXQODNIBUNQWAS-CIUDSAMLSA-N Ala-Gln-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CXQODNIBUNQWAS-CIUDSAMLSA-N 0.000 description 1
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- NOGFDULFCFXBHB-CIUDSAMLSA-N Ala-Leu-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N NOGFDULFCFXBHB-CIUDSAMLSA-N 0.000 description 1
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- HCBKAOZYACJUEF-XQXXSGGOSA-N Ala-Thr-Gln Chemical compound N[C@@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O HCBKAOZYACJUEF-XQXXSGGOSA-N 0.000 description 1
- PHQXWZGXKAFWAZ-ZLIFDBKOSA-N Ala-Trp-Lys Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 PHQXWZGXKAFWAZ-ZLIFDBKOSA-N 0.000 description 1
- AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 1
- XKHLBBQNPSOGPI-GUBZILKMSA-N Ala-Val-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N XKHLBBQNPSOGPI-GUBZILKMSA-N 0.000 description 1
- ANNKVZSFQJGVDY-XUXIUFHCSA-N Ala-Val-Pro-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 ANNKVZSFQJGVDY-XUXIUFHCSA-N 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- DBKNLHKEVPZVQC-LPEHRKFASA-N Arg-Ala-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O DBKNLHKEVPZVQC-LPEHRKFASA-N 0.000 description 1
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 1
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 1
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
- WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 description 1
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 1
- AIFHRTPABBBHKU-RCWTZXSCSA-N Arg-Thr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AIFHRTPABBBHKU-RCWTZXSCSA-N 0.000 description 1
- GMRGSBAMMMVDGG-GUBZILKMSA-N Asn-Arg-Arg Chemical compound C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N GMRGSBAMMMVDGG-GUBZILKMSA-N 0.000 description 1
- JEPNYDRDYNSFIU-QXEWZRGKSA-N Asn-Arg-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(O)=O JEPNYDRDYNSFIU-QXEWZRGKSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- AXXCUABIFZPKPM-BQBZGAKWSA-N Asp-Arg-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O AXXCUABIFZPKPM-BQBZGAKWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- KYFSMWLWHYZRNW-ACZMJKKPSA-N Gln-Asp-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N KYFSMWLWHYZRNW-ACZMJKKPSA-N 0.000 description 1
- SMLDOQHTOAAFJQ-WDSKDSINSA-N Gln-Gly-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SMLDOQHTOAAFJQ-WDSKDSINSA-N 0.000 description 1
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 1
- ZBKUIQNCRIYVGH-SDDRHHMPSA-N Gln-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZBKUIQNCRIYVGH-SDDRHHMPSA-N 0.000 description 1
- ININBLZFFVOQIO-JHEQGTHGSA-N Gln-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O ININBLZFFVOQIO-JHEQGTHGSA-N 0.000 description 1
- RJONUNZIMUXUOI-GUBZILKMSA-N Glu-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N RJONUNZIMUXUOI-GUBZILKMSA-N 0.000 description 1
- HJIFPJUEOGZWRI-GUBZILKMSA-N Glu-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N HJIFPJUEOGZWRI-GUBZILKMSA-N 0.000 description 1
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- QNJNPKSWAHPYGI-JYJNAYRXSA-N Glu-Phe-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 QNJNPKSWAHPYGI-JYJNAYRXSA-N 0.000 description 1
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 1
- RQZGFWKQLPJOEQ-YUMQZZPRSA-N Gly-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN)CN=C(N)N RQZGFWKQLPJOEQ-YUMQZZPRSA-N 0.000 description 1
- LJXWZPHEMJSNRC-KBPBESRZSA-N Gly-Gln-Trp Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O LJXWZPHEMJSNRC-KBPBESRZSA-N 0.000 description 1
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- HQSKKSLNLSTONK-JTQLQIEISA-N Gly-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 HQSKKSLNLSTONK-JTQLQIEISA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- PMWSGVRIMIFXQH-KKUMJFAQSA-N His-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)C1=CN=CN1 PMWSGVRIMIFXQH-KKUMJFAQSA-N 0.000 description 1
- QMUHTRISZMFKAY-MXAVVETBSA-N His-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N QMUHTRISZMFKAY-MXAVVETBSA-N 0.000 description 1
- BPOHQCZZSFBSON-KKUMJFAQSA-N His-Leu-His Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O BPOHQCZZSFBSON-KKUMJFAQSA-N 0.000 description 1
- LNDVNHOSZQPJGI-AVGNSLFASA-N His-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNDVNHOSZQPJGI-AVGNSLFASA-N 0.000 description 1
- XHQYFGPIRUHQIB-PBCZWWQYSA-N His-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CN=CN1 XHQYFGPIRUHQIB-PBCZWWQYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- JNLSTRPWUXOORL-MMWGEVLESA-N Ile-Ser-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N JNLSTRPWUXOORL-MMWGEVLESA-N 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 1
- GLBNEGIOFRVRHO-JYJNAYRXSA-N Leu-Gln-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GLBNEGIOFRVRHO-JYJNAYRXSA-N 0.000 description 1
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 1
- HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- BTEMNFBEAAOGBR-BZSNNMDCSA-N Leu-Tyr-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BTEMNFBEAAOGBR-BZSNNMDCSA-N 0.000 description 1
- UFPLDOKWDNTTRP-ULQDDVLXSA-N Leu-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=C(O)C=C1 UFPLDOKWDNTTRP-ULQDDVLXSA-N 0.000 description 1
- DGAAQRAUOFHBFJ-CIUDSAMLSA-N Lys-Asn-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O DGAAQRAUOFHBFJ-CIUDSAMLSA-N 0.000 description 1
- ULUQBUKAPDUKOC-GVXVVHGQSA-N Lys-Glu-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O ULUQBUKAPDUKOC-GVXVVHGQSA-N 0.000 description 1
- UQRZFMQQXXJTTF-AVGNSLFASA-N Lys-Lys-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O UQRZFMQQXXJTTF-AVGNSLFASA-N 0.000 description 1
- SPNKGZFASINBMR-IHRRRGAJSA-N Lys-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCCN)N SPNKGZFASINBMR-IHRRRGAJSA-N 0.000 description 1
- AZOFEHCPMBRNFD-BZSNNMDCSA-N Lys-Phe-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 AZOFEHCPMBRNFD-BZSNNMDCSA-N 0.000 description 1
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 description 1
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
- ACYHZNZHIZWLQF-BQBZGAKWSA-N Met-Asn-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O ACYHZNZHIZWLQF-BQBZGAKWSA-N 0.000 description 1
- NCFZHKMKRCYQBJ-CIUDSAMLSA-N Met-Cys-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N NCFZHKMKRCYQBJ-CIUDSAMLSA-N 0.000 description 1
- CGUYGMFQZCYJSG-DCAQKATOSA-N Met-Lys-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O CGUYGMFQZCYJSG-DCAQKATOSA-N 0.000 description 1
- DJJBHQHOZLUBCN-WDSOQIARSA-N Met-Lys-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DJJBHQHOZLUBCN-WDSOQIARSA-N 0.000 description 1
- WXXNVZMWHOLNRJ-AVGNSLFASA-N Met-Pro-Lys Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O WXXNVZMWHOLNRJ-AVGNSLFASA-N 0.000 description 1
- MIXPUVSPPOWTCR-FXQIFTODSA-N Met-Ser-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MIXPUVSPPOWTCR-FXQIFTODSA-N 0.000 description 1
- YJNDFEWPGLNLNH-IHRRRGAJSA-N Met-Tyr-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CS)C(O)=O)CC1=CC=C(O)C=C1 YJNDFEWPGLNLNH-IHRRRGAJSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 1
- KOUUGTKGEQZRHV-KKUMJFAQSA-N Phe-Gln-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O KOUUGTKGEQZRHV-KKUMJFAQSA-N 0.000 description 1
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 1
- BSJCSHIAMSGQGN-BVSLBCMMSA-N Phe-Pro-Trp Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O BSJCSHIAMSGQGN-BVSLBCMMSA-N 0.000 description 1
- ZYNBEWGJFXTBDU-ACRUOGEOSA-N Phe-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N ZYNBEWGJFXTBDU-ACRUOGEOSA-N 0.000 description 1
- FRMKIPSIZSFTTE-HJOGWXRNSA-N Phe-Tyr-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FRMKIPSIZSFTTE-HJOGWXRNSA-N 0.000 description 1
- ALJGSKMBIUEJOB-FXQIFTODSA-N Pro-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 ALJGSKMBIUEJOB-FXQIFTODSA-N 0.000 description 1
- AJLVKXCNXIJHDV-CIUDSAMLSA-N Pro-Ala-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O AJLVKXCNXIJHDV-CIUDSAMLSA-N 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- FKKHDBFNOLCYQM-FXQIFTODSA-N Pro-Cys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O FKKHDBFNOLCYQM-FXQIFTODSA-N 0.000 description 1
- UPJGUQPLYWTISV-GUBZILKMSA-N Pro-Gln-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UPJGUQPLYWTISV-GUBZILKMSA-N 0.000 description 1
- SKICPQLTOXGWGO-GARJFASQSA-N Pro-Gln-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N2CCC[C@@H]2C(=O)O SKICPQLTOXGWGO-GARJFASQSA-N 0.000 description 1
- WFHYFCWBLSKEMS-KKUMJFAQSA-N Pro-Glu-Phe Chemical compound N([C@@H](CCC(=O)O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 WFHYFCWBLSKEMS-KKUMJFAQSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- FHZJRBVMLGOHBX-GUBZILKMSA-N Pro-Pro-Asp Chemical compound OC(=O)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1)C(O)=O FHZJRBVMLGOHBX-GUBZILKMSA-N 0.000 description 1
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 1
- 101710150344 Protein Rev Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 1
- CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 description 1
- ZUDXUJSYCCNZQJ-DCAQKATOSA-N Ser-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CO)N ZUDXUJSYCCNZQJ-DCAQKATOSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- BSXKBOUZDAZXHE-CIUDSAMLSA-N Ser-Pro-Glu Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O BSXKBOUZDAZXHE-CIUDSAMLSA-N 0.000 description 1
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- DGDCHPCRMWEOJR-FQPOAREZSA-N Thr-Ala-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DGDCHPCRMWEOJR-FQPOAREZSA-N 0.000 description 1
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 1
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 1
- FHDLKMFZKRUQCE-HJGDQZAQSA-N Thr-Glu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FHDLKMFZKRUQCE-HJGDQZAQSA-N 0.000 description 1
- ODXKUIGEPAGKKV-KATARQTJSA-N Thr-Leu-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O ODXKUIGEPAGKKV-KATARQTJSA-N 0.000 description 1
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 description 1
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- ZHDQRPWESGUDST-JBACZVJFSA-N Trp-Phe-Gln Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CC=CC=C1 ZHDQRPWESGUDST-JBACZVJFSA-N 0.000 description 1
- JBBYKPZAPOLCPK-JYJNAYRXSA-N Tyr-Arg-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O JBBYKPZAPOLCPK-JYJNAYRXSA-N 0.000 description 1
- UNUZEBFXGWVAOP-DZKIICNBSA-N Tyr-Glu-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UNUZEBFXGWVAOP-DZKIICNBSA-N 0.000 description 1
- QARCDOCCDOLJSF-HJPIBITLSA-N Tyr-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QARCDOCCDOLJSF-HJPIBITLSA-N 0.000 description 1
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 1
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 1
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 description 1
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 1
- UZDHNIJRRTUKKC-DLOVCJGASA-N Val-Gln-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N UZDHNIJRRTUKKC-DLOVCJGASA-N 0.000 description 1
- ROLGIBMFNMZANA-GVXVVHGQSA-N Val-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N ROLGIBMFNMZANA-GVXVVHGQSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 108010060455 des-Tyr- beta-casomorphin Proteins 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010043322 lysyl-tryptophyl-alpha-lysine Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010091617 pentalysine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 108010007375 seryl-seryl-seryl-arginine Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及生物医药技术领域,尤其涉及包含胰岛样细胞团的制剂。本发明提供了包含胰岛样细胞团的制剂及其制备方法,该制剂可降解,在显微镜下可见微球形态完整,粒径分布均匀。将该微球在体外培养,可发现微囊内干细胞扩增,并开始逐渐形成胚体类组织形态,同时进行检测,可在囊体外培养基检测到Pdx‑1‑Linker‑IGF‑1和胰岛素存在,证明该细胞逐渐向类胰腺组织演变并可以释放胰岛素,其最终可用于体内移植修复胰岛功能。
Description
技术领域
本发明涉及生物医药技术领域,尤其涉及包含胰岛样细胞团的制剂。
背景技术
糖尿病(Diabetes Mellitus,DM)是一组以高血糖为特征的代谢性疾病。高血糖则是由于胰岛素分泌缺陷或其生物作用受损,或两者兼有引起。糖尿病时长期存在的高血糖,导致各种组织,特别是眼、肾、心脏、血管、神经的慢性损害、功能障碍。
据世界卫生组织推荐的分型,可将糖尿病分为以胰岛素绝对不足为主的I型糖尿病和以胰岛素相对不足且胰岛素抵抗为主的II型糖尿病两种类型。其中,约10%的患者属于I型糖尿病,遗传因素在该型糖尿病中的重要性高达50%,发病常见于儿童和青少年人群。另外,90%的患者属于II型糖尿病,是一种多基因遗传因素、环境因素联合作用引起的代谢性疾病,具有很高的遗传倾向,多见于40岁以上的成年患者。
目前在糖尿病的临床治疗上,通过注射胰岛素来控制血糖虽然是一种有效的缓解措施,但并不能彻底治愈糖尿病,还有可能造成低血糖等风。真正根治糖尿病将是恢复机体内功能性胰岛β细胞的数量和消除糖尿病引发的各种并发症。其中,进行胰岛移植是治疗I型糖尿病和部分II型糖尿病最有效的方法之一。但是,由于供体来源严重不足以及器官移植将面临终身免疫抑制治疗等问题,极大地限制了胰岛移植在临床治疗上的广泛应用。
近年来,由干细胞体外定向诱导分化成胰腺祖细胞和功能性胰岛来进行移植,为我们提供了一个全新的细胞替代疗法。但是,目前细胞在体内的修复效果欠佳,尚无法满足临床的应用。因此,应进一步研究,提高胰岛样细胞团在体内的。
发明内容
有鉴于此,本发明要解决的技术问题在于提供包含胰岛样细胞团的制剂,该制剂具有良好的体内移植修复胰岛的功能。
本发明提供了包含胰岛样细胞团的制剂的制备方法,包括:
步骤1:将壳聚糖溶解于乙酸溶液,灭菌制得壳聚糖溶液;将胶原蛋白溶解于乙酸溶液,灭菌制得胶原蛋白溶液;
步骤2:将壳聚糖溶液与胶原蛋白溶液混合,以京尼平为交联剂进行交联制得降解材料;
步骤3:将降解材料与胰岛样细胞团混合,然后与含有乳化剂的植物油混合,加入固化剂于0~4℃搅拌2~5min,然后升温至35~40℃固化20~30min,制得所述制剂。
本发明实施例中,所述壳聚糖为90%脱乙酰化的低分子量壳聚糖。
本发明实施例中,所述壳聚糖溶液中,乙酸的质量分数为1%,壳聚糖的质量分数为1%。
本发明实施例中,所述壳聚糖溶液的灭菌为高温灭菌,120℃灭菌20min。
本发明实施例中,所述胶原蛋白为I型胶原蛋白。
本发明实施例中,所述胶原蛋白溶液中,乙酸的质量分数为1%,胶原蛋白的质量分数为3%。
本发明实施例中,所述胶原蛋白溶液的灭菌为高温灭菌,120℃灭菌20min。
本发明实施例中,步骤2中所述壳聚糖溶液与胶原蛋白溶液的体积比为1:1。
本发明实施例中,所述京尼平与壳聚糖溶液的质量-体积比为1g:100mL;所述交联的条件为常温反应1小时。
本发明实施例中,步骤3中所述胰岛样细胞团在降解材料中的密度为1×106cell/mL。
本发明实施例中,所述乳化剂为Span80,在植物油中的质量分数为15%。
本发明实施例中,所述固化剂为京尼平,在植物油中的质量分数为1%。
本发明实施例中,加入固化剂后,0℃搅拌3min,然后升温至37℃固化25min。
本发明实施例中,所述固化后还包括离心取沉淀、生理盐水清洗的步骤。
一些实施例中,所述离心的条件为200g,5min。
一些实施例中,所述生理盐水清洗的次数为3次。
本发明实施例中,所述胰岛样细胞团由骨髓干细胞诱导分化制得。
本发明实施例中,所述骨髓干细胞为表达融合蛋白Pdx-1-Linker-IGF-1的骨髓干细胞;所述诱导分化的培养基为含有30mmol/L葡萄糖和10mmol/LC肽的完全培养基。
表达融合蛋白Pdx-1-Linker-IGF-1的骨髓干细胞的制备方法,其以慢病毒感染骨髓干细胞获得。所述慢病毒由含有表达融合蛋白Pdx-1-Linker-IGF-1的DNA分子的质粒载体与慢病毒包装质粒共转染293T细胞构建获得。
所述慢病毒包装质粒为pMD2G(表达VSV G包膜蛋白)和pCMVR8.74(表达HIV-1Gag,Pol,Tat and Rev蛋白)。所述共转染采用CaCl2转染。
所述慢病毒的制备方法为:将293T细胞与本发明所述的质粒载体和pMD2G、pCMVR8.74质粒混合,以含有CaCl2的HeBS缓冲液,37℃,5%CO2培养后收集上清液,经过滤、离心收集病毒。
所述感染为:将病毒悬液和完全培养基混合后加入含有干细胞的培养皿中,37℃孵育。4小时后,再加入一定量的完全培养基,37℃孵育,继续培养24小时,用新鲜培养基替换含有病毒的培养基,继续培养获得所述干细胞。
本发明制备方法制得的包含胰岛样细胞团的制剂。
本发明制备方法制得的包含胰岛样细胞团的制剂在制备治疗糖尿病的药物中的应用。
本发明还提供了一种糖尿病的制备方法,其为给予本发明提供的包含胰岛样细胞团的制剂。
本发明提供了包含胰岛样细胞团的制剂及其制备方法,该制剂可降解,在显微镜下可见微球形态完整,粒径分布均匀。将该微球在体外培养,可发现微囊内干细胞扩增,并开始逐渐形成胚体类组织形态,同时进行检测,可在囊体外培养基检测到Pdx-1-Linker-IGF-1和胰岛素存在,证明该细胞逐渐向类胰腺组织演变并可以释放胰岛素,其最终可用于体内移植修复胰岛功能。
附图说明
图1示微球的显微镜检测结果;
图2示10天内胰岛素分泌量检测结果;
图3示10天干细胞转化效率结果;
图4示10天干细胞成团效率结果;
图5示10天干细胞成团的组织形态。
具体实施方式
本发明提供了包含胰岛样细胞团的制剂,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
本发明采用的试材皆为普通市售品,皆可于市场购得。
下面结合实施例,进一步阐述本发明:
实施例1
1、质粒制备:
人工合成SEQ ID NO:2所示的DNA片段,以BamH I,Sal I,酶切位点BamH I:G^GATCC,4021,Sal I:G^TCGAC,4049位点连接入载体pRRLSIN.cPPT.PGK-WPRE,构建获得表达融合蛋白Pdx-1-Linker-IGF-1的质粒载体(全序列如SEQ ID NO:3所示)。
2、病毒制备:
A:293T细胞使用含10%FBS,+penicillin-streptomycin抗生素的DMEM培养基(完全培养基)进行培养,按15ml培养皿为例,加入8×106细胞,22.5ml完全培养基,37℃,5%CO2进行培养。B:过夜培养后,更换为无血清培养基DMEM。C:按一定比例将3个质粒(pMD2G、pCMVR8.74、pRRLSIN.cPPT.PGK-WPRE-Pdx-1-Linker-IGF-1)进行混合,缓冲液为HeBS。D:转染方法采用CaCl2转染方案,将CaCl2按一定比例和含有3质粒的HeBS缓冲液混合,充分混匀后,加入到293T培养皿中,37℃,5%CO2进行培养。E:过夜培养后,将培养基吸出,重新更换完全培养基继续培养,37℃,5%CO2进行培养。F:培养24小时后,轻轻的吸尘细胞培养基,4℃保存,再更换新鲜完全培养基。G:培养24小时后,轻轻的吸出细胞培养基,4℃保存。H:将两次收集到的细胞培养上清,通过0.45um滤膜进行过滤,去除杂质,4℃保存。I:将过滤后的培养上清,移入离心管中,25000转,4℃,离心120分钟,离心后去除上清,沉淀即为病毒,用PBS重悬,-80℃保存。
3、细胞转染:
离心提取骨髓组织的MNC(单核细胞),PBS清洗后,将细胞悬浮在8-10ml生理盐水(2.2-3.8×108cells)。使用完全培养基:含10%FBS(胎牛血清)的干细胞培养基(北京达科为生物技术有限公司:Mesenchymal Stem Cell Basal Medium(MSCBM),人间充质干细胞基础培养基),加青大霉素和青霉素,37度,5%CO2的条件下进行贴壁培养,扩增传代2次后,细胞扩增效率平稳并且活率达到98%时,用于细胞转染。
4、干细胞感染:
将培养好的干细胞重新贴壁培养,加完全培养基,过夜培养,第二天将培养基吸出,将一定量的病毒悬液和完全培养基混合后加入培养皿中,37℃孵育。4小时后,再加入一定量的完全培养基,37℃孵育,继续培养24小时,用新鲜完全培养基替换含有病毒的培养基,继续培养10d,获得胰岛样细胞团。
实施例2
把90%脱乙酰化的低分子量的壳聚糖溶解于1%醋酸中,得到最终2%比重的溶液;120℃灭菌处理20分钟。
取1型胶原蛋白,溶解在乙酸1%中得到4%比重溶液,120℃灭菌处理20分钟。
按照1:1体积比混合壳聚糖溶液和胶原蛋白溶液,采用京尼平作为交联剂,促使壳聚糖和胶原蛋白发生交联反应,制得可降解材料,交联条件为室温(18~30℃)反应1小时。
以1×106cell/ml的浓度在可降解材料后中加入实施例1制得的胰岛样细胞团4℃下混合均匀,加入0℃的含有15%Span80的无菌植物油中,然后保持0℃加入固化剂京尼平,充分搅拌3分钟。
再将温度升高至室温,反应60min,充分固化后,形成包含分泌胰岛细胞的壳聚糖/胶原的微球。最后进行离心(200g,5分钟),提取沉淀(细胞微球),再用生理盐水清洗三次,离心沉淀后将微球悬浮于生理盐水中,显微镜下观察,结果如图1。
对比例1
Pdx-1-Linker-IGF-1融合蛋白表达
利用Pet32表达系统,采用大肠杆菌BL21进行Pdx-1-Linker-IGF-1融合蛋白表达,并利用分子筛进行纯化,纯化后的蛋白在-80度冷冻保存,用于后期实验。
将大肠杆菌表达外源Pdx-1-Linker-IGF-1融合蛋白(浓度为100pg/ml)每两天更换培养基并同时补充Pdx-1-Linker-IGF-1融合蛋白,连续培养10天,获得胰岛样细胞团。将该细胞团按照实施例2的方法制备包含分泌胰岛细胞的壳聚糖/胶原的微球。
对比例2
Pdx-1-Linker-IGF-1融合蛋白表达
利用Pet32表达系统,采用大肠杆菌BL21进行Pdx-1-Linker-IGF-1融合蛋白表达,并利用分子筛进行纯化,纯化后的蛋白在-80度冷冻保存,用于后期实验。
将大肠杆菌表达外源Pdx-1-Linker-IGF-1融合蛋白(浓度为100pg/ml)每两天更换培养基并同时补充Pdx-1-Linker-IGF-1融合蛋白,连续培养5天后,继续培养同时,只加入培养基,不添加Pdx-1-Linker-IGF-1融合蛋白,继续培养5天,获得胰岛样细胞团。将该细胞团按照实施例2的方法制备包含分泌胰岛细胞的壳聚糖/胶原的微球。
效果验证
对实施例2(MSCT组)、对比例1(MSC-1)和对比例2(MSC-2)制得的微球进行检测。
1、胰岛素分泌量鉴定
将实施例2(MSCT组)、对比例1(MSC-1)和对比例2(MSC-2)制得的微球,在培养期间,每隔两天提取一次微球,大约为总量的5%,进行双硫腙检测以及显微镜下检测,同时每天提取培养基进行胰岛素分泌鉴定。结果如图2~4。
MSC-1组微球的测量结果显示,10天培养过程中,胰岛素分泌量持续升高,最终达到65±20pg/ml,但是双硫腙染色实验表明,转化效率没用明显提高同时成团效果保持不变。MSC-2组微球组,在前五天的检测中表明胰岛素分泌量持续提高可到达59±17pg/ml左右,但是停止加入Pdx-1-Linker-IGF-1融合蛋白后,分泌量无明显变化:57±17pg/ml,同时10天的检测结果表明转化率和成团率基本无差别。MSCT微球组,10天的检测结果显示,胰岛素分泌量升高明显:85±15pg/ml左右,同时双硫腙染色实验表明其转化率和成团效果也明显提高:75%±5%,80%±12%。因此拥有内源表达的干细胞具有更强的转化效率和胰岛素分泌能力,在外源蛋白停止加入后,干细胞的诱导进程停止,表明内源表达的融合蛋白相对外源具有非常强的活性,并对促进干细胞的转化具有更好的效用。
2、利用MSCT组的细胞制备出载有干细胞的微球,提取总量相当于1×107细胞总量制备的微球,加含有葡萄糖(浓度为30mmol/L)的完全培养基,进行培养,培养24小时,提取培养上清液,检测胰岛素和Pdx-1-Linker-IGF-1融合蛋白分泌效果,检测合格标准为胰岛素:95±22pg/ml,Pdx-1-Linker-IGF-1融合蛋白50±10pg/ml,如检测分泌效果未达标,则视为微球制备失败,需要重新制备。
3、对MSCT组的微球,在微球检测合格后,继续培养10d并观察,在显微镜下观察,可发现微囊内干细胞扩增,并开始逐渐形成胚体类组织形态(如图5),同时进行检测,可在囊体外培养基发现Pdx-1-Linker-IGF-1和胰岛素,说明细胞逐渐向类胰腺组织演变并可以释放胰岛素,其最终可用于体内移植修复胰岛功能。
以上仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 长春万成生物电子工程有限公司
<120> 包含胰岛样细胞团的制剂
<130> MP1806682
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 463
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Met Asn Gly Glu Glu Gln Tyr Tyr Ala Ala Thr Gln Leu Tyr Lys Asp
1 5 10 15
Pro Cys Ala Phe Gln Arg Gly Pro Ala Pro Glu Phe Ser Ala Ser Pro
20 25 30
Pro Ala Cys Leu Tyr Met Gly Arg Gln Pro Pro Pro Pro Pro Pro His
35 40 45
Pro Phe Pro Gly Ala Leu Gly Ala Leu Glu Gln Gly Ser Pro Pro Asp
50 55 60
Ile Ser Pro Tyr Glu Val Pro Pro Leu Ala Asp Asp Pro Ala Val Ala
65 70 75 80
His Leu His His His Leu Pro Ala Gln Leu Ala Leu Pro His Pro Pro
85 90 95
Ala Gly Pro Phe Pro Glu Gly Ala Glu Pro Gly Val Leu Glu Glu Pro
100 105 110
Asn Arg Val Gln Leu Pro Phe Pro Trp Met Lys Ser Thr Lys Ala His
115 120 125
Ala Trp Lys Gly Gln Trp Ala Gly Gly Ala Tyr Ala Ala Glu Pro Glu
130 135 140
Glu Asn Lys Arg Thr Arg Thr Ala Tyr Thr Arg Ala Gln Leu Leu Glu
145 150 155 160
Leu Glu Lys Glu Phe Leu Phe Asn Lys Tyr Ile Ser Arg Pro Arg Arg
165 170 175
Val Glu Leu Ala Val Met Leu Asn Leu Thr Glu Arg His Ile Lys Ile
180 185 190
Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys Glu Glu Asp Lys Lys
195 200 205
Arg Gly Gly Gly Thr Ala Val Gly Gly Gly Gly Val Ala Glu Pro Glu
210 215 220
Gln Asp Cys Ala Val Thr Ser Gly Glu Glu Leu Leu Ala Leu Pro Pro
225 230 235 240
Pro Pro Pro Pro Gly Gly Ala Val Pro Pro Ala Ala Pro Val Ala Ala
245 250 255
Arg Glu Gly Arg Leu Pro Pro Gly Leu Ser Ala Ser Pro Gln Pro Ser
260 265 270
Ser Val Ala Pro Arg Arg Pro Gln Glu Pro Arg Gly Gly Gly Gly Ser
275 280 285
Gly Gly Gly Gly Ser Met Cys Gln Ser Pro Glu Ser His Val Glu Lys
290 295 300
Lys Lys Lys Lys Lys Phe Lys Val Gln Val Ile Ser Thr Thr Pro Gly
305 310 315 320
Lys Pro Gly Leu Glu Ser Ser Leu Gly Lys Glu Val Lys Met His Thr
325 330 335
Met Ser Ser Ser His Leu Phe Tyr Leu Ala Leu Cys Leu Leu Thr Phe
340 345 350
Thr Ser Ser Ala Thr Ala Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu
355 360 365
Val Asp Ala Leu Gln Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn
370 375 380
Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly
385 390 395 400
Ile Val Asp Glu Cys Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu
405 410 415
Met Tyr Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala Arg Ser Val Arg
420 425 430
Ala Gln Arg His Thr Asp Met Pro Lys Thr Gln Lys Glu Val His Leu
435 440 445
Lys Asn Ala Ser Arg Gly Ser Ala Gly Asn Lys Asn Tyr Arg Met
450 455 460
<210> 2
<211> 1392
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
atgaacggcg aggagcagta ctacgcggcc acgcagcttt acaaggaccc atgcgcgttc 60
cagcgaggcc cggcgccgga gttcagcgcc agcccccctg cgtgcctgta catgggccgc 120
cagcccccgc cgccgccgcc gcacccgttc cctggcgccc tgggcgcgct ggagcagggc 180
agccccccgg acatctcccc gtacgaggtg ccccccctcg ccgacgaccc cgcggtggcg 240
caccttcacc accacctccc ggctcagctc gcgctccccc acccgcccgc cgggcccttc 300
ccggagggag ccgagccggg cgtcctggag gagcccaacc gcgtccagct gcctttccca 360
tggatgaagt ctaccaaagc tcacgcgtgg aaaggccagt gggcaggcgg cgcctacgct 420
gcggagccgg aggagaacaa gcggacgcgc acggcctaca cgcgcgcaca gctgctagag 480
ctggagaagg agttcctatt caacaagtac atctcacggc cgcgccgggt ggagctggct 540
gtcatgttga acttgaccga gagacacatc aagatctggt tccaaaaccg ccgcatgaag 600
tggaaaaagg aggaggacaa gaagcgcggc ggcgggacag ctgtcggggg tggcggggtc 660
gcggagcctg agcaggactg cgccgtgacc tccggcgagg agcttctggc gctgccgccg 720
ccgccgcccc ccggaggtgc tgtgccgccc gctgcccccg ttgccgcccg agagggccgc 780
ctgccgcctg gccttagcgc gtcgccacag ccctccagcg tcgcgcctcg gcggccgcag 840
gaaccacgag gtggcggagg gagtgggggt ggaggctcta tgtgtcagtc ccctgagagt 900
catgtggaaa aaaaaaaaaa gaaaaaattc aaggtccagg ttatttccac cactcctggg 960
aaaccaggcc tggagagctc tctagggaaa gaggtgaaga tgcacaccat gtcctcctcg 1020
catctcttct acctggcgct gtgcctgctc accttcacca gctctgccac ggctggaccg 1080
gagacgctct gcggggctga gctggtggat gctcttcagt tcgtgtgtgg agacaggggc 1140
ttttatttca acaagcccac agggtatggc tccagcagtc ggagggcgcc tcagacaggc 1200
atcgtggatg agtgctgctt ccggagctgt gatctaagga ggctggagat gtattgcgca 1260
cccctcaagc ctgccaagtc agctcgctct gtccgtgccc agcgccacac cgacatgccc 1320
aagacccaga aggaagtaca tttgaagaac gcaagtagag ggagtgcagg aaacaagaac 1380
tacaggatgt ag 1392
<210> 3
<211> 8060
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
agcttaatgt agtcttatgc aatactcttg tagtcttgca acatggtaac gatgagttag 60
caacatgcct tacaaggaga gaaaaagcac cgtgcatgcc gattggtgga agtaaggtgg 120
tacgatcgtg ccttattagg aaggcaacag acgggtctga catggattgg acgaaccact 180
gaattgccgc attgcagaga tattgtattt aagtgcctag ctcgatacat aaacgggtct 240
ctctggttag accagatctg agcctgggag ctctctggct aactagggaa cccactgctt 300
aagcctcaat aaagcttgcc ttgagtgctt caagtagtgt gtgcccgtct gttgtgtgac 360
tctggtaact agagatccct cagacccttt tagtcagtgt ggaaaatctc tagcagtggc 420
gcccgaacag ggacttgaaa gcgaaaggga aaccagagga gctctctcga cgcaggactc 480
ggcttgctga agcgcgcacg gcaagaggcg aggggcggcg actggtgagt acgccaaaaa 540
ttttgactag cggaggctag aaggagagag atgggtgcga gagcgtcagt attaagcggg 600
ggagaattag atcgcgatgg gaaaaaattc ggttaaggcc agggggaaag aaaaaatata 660
aattaaaaca tatagtatgg gcaagcaggg agctagaacg attcgcagtt aatcctggcc 720
tgttagaaac atcagaaggc tgtagacaaa tactgggaca gctacaacca tcccttcaga 780
caggatcaga agaacttaga tcattatata atacagtagc aaccctctat tgtgtgcatc 840
aaaggataga gataaaagac accaaggaag ctttagacaa gatagaggaa gagcaaaaca 900
aaagtaagac caccgcacag caagcggccg ctgatcttca gacctggagg aggagatatg 960
agggacaatt ggagaagtga attatataaa tataaagtag taaaaattga accattagga 1020
gtagcaccca ccaaggcaaa gagaagagtg gtgcagagag aaaaaagagc agtgggaata 1080
ggagctttgt tccttgggtt cttgggagca gcaggaagca ctatgggcgc agcgtcaatg 1140
acgctgacgg tacaggccag acaattattg tctggtatag tgcagcagca gaacaatttg 1200
ctgagggcta ttgaggcgca acagcatctg ttgcaactca cagtctgggg catcaagcag 1260
ctccaggcaa gaatcctggc tgtggaaaga tacctaaagg atcaacagct cctggggatt 1320
tggggttgct ctggaaaact catttgcacc actgctgtgc cttggaatgc tagttggagt 1380
aataaatctc tggaacagat ttggaatcac acgacctgga tggagtggga cagagaaatt 1440
aacaattaca caagcttaat acactcctta attgaagaat cgcaaaacca gcaagaaaag 1500
aatgaacaag aattattgga attagataaa tgggcaagtt tgtggaattg gtttaacata 1560
acaaattggc tgtggtatat aaaattattc ataatgatag taggaggctt ggtaggttta 1620
agaatagttt ttgctgtact ttctatagtg aatagagtta ggcagggata ttcaccatta 1680
tcgtttcaga cccacctccc aaccccgagg ggacccgaca ggcccgaagg aatagaagaa 1740
gaaggtggag agagagacag agacagatcc attcgattag tgaacggatc tcgacggtat 1800
cggttaactt ttaaaagaaa aggggggatt ggggggtaca gtgcagggga aagaatagta 1860
gacataatag caacagacat acaaactaaa gaattacaaa aacaaattac aaaaattcaa 1920
aattttatcg atcacgagac tagcctcgag aagcttgata tcgaattcca cggggttggg 1980
gttgcgcctt ttccaaggca gccctgggtt tgcgcaggga cgcggctgct ctgggcgtgg 2040
ttccgggaaa cgcagcggcg ccgaccctgg gtctcgcaca ttcttcacgt ccgttcgcag 2100
cgtcacccgg atcttcgccg ctacccttgt gggccccccg gcgacgcttc ctgctccgcc 2160
cctaagtcgg gaaggttcct tgcggttcgc ggcgtgccgg acgtgacaaa cggaagccgc 2220
acgtctcact agtaccctcg cagacggaca gcgccaggga gcaatggcag cgcgccgacc 2280
gcgatgggct gtggccaata gcggctgctc agcagggcgc gccgagagca gcggccggga 2340
aggggcggtg cgggaggcgg ggtgtggggc ggtagtgtgg gccctgttcc tgcccgcgcg 2400
gtgttccgca ttctgcaagc ctccggagcg cacgtcggca gtcggctccc tcgttgaccg 2460
aatcaccgac ctctctcccc agggggatcc accggtcgcc accatgaacg gcgaggagca 2520
gtactacgcg gccacgcagc tttacaagga cccatgcgcg ttccagcgag gcccggcgcc 2580
ggagttcagc gccagccccc ctgcgtgcct gtacatgggc cgccagcccc cgccgccgcc 2640
gccgcacccg ttccctggcg ccctgggcgc gctggagcag ggcagccccc cggacatctc 2700
cccgtacgag gtgccccccc tcgccgacga ccccgcggtg gcgcaccttc accaccacct 2760
cccggctcag ctcgcgctcc cccacccgcc cgccgggccc ttcccggagg gagccgagcc 2820
gggcgtcctg gaggagccca accgcgtcca gctgcctttc ccatggatga agtctaccaa 2880
agctcacgcg tggaaaggcc agtgggcagg cggcgcctac gctgcggagc cggaggagaa 2940
caagcggacg cgcacggcct acacgcgcgc acagctgcta gagctggaga aggagttcct 3000
attcaacaag tacatctcac ggccgcgccg ggtggagctg gctgtcatgt tgaacttgac 3060
cgagagacac atcaagatct ggttccaaaa ccgccgcatg aagtggaaaa aggaggagga 3120
caagaagcgc ggcggcggga cagctgtcgg gggtggcggg gtcgcggagc ctgagcagga 3180
ctgcgccgtg acctccggcg aggagcttct ggcgctgccg ccgccgccgc cccccggagg 3240
tgctgtgccg cccgctgccc ccgttgccgc ccgagagggc cgcctgccgc ctggccttag 3300
cgcgtcgcca cagccctcca gcgtcgcgcc tcggcggccg caggaaccac gaggtggcgg 3360
agggagtggg ggtggaggct ctatgtgtca gtcccctgag agtcatgtgg aaaaaaaaaa 3420
aaagaaaaaa ttcaaggtcc aggttatttc caccactcct gggaaaccag gcctggagag 3480
ctctctaggg aaagaggtga agatgcacac catgtcctcc tcgcatctct tctacctggc 3540
gctgtgcctg ctcaccttca ccagctctgc cacggctgga ccggagacgc tctgcggggc 3600
tgagctggtg gatgctcttc agttcgtgtg tggagacagg ggcttttatt tcaacaagcc 3660
cacagggtat ggctccagca gtcggagggc gcctcagaca ggcatcgtgg atgagtgctg 3720
cttccggagc tgtgatctaa ggaggctgga gatgtattgc gcacccctca agcctgccaa 3780
gtcagctcgc tctgtccgtg cccagcgcca caccgacatg cccaagaccc agaaggaagt 3840
acatttgaag aacgcaagta gagggagtgc aggaaacaag aactacagga tgtagagcgg 3900
ccgcgtcgac aatcaacctc tggattacaa aatttgtgaa agattgactg gtattcttaa 3960
ctatgttgct ccttttacgc tatgtggata cgctgcttta atgcctttgt atcatgctat 4020
tgcttcccgt atggctttca ttttctcctc cttgtataaa tcctggttgc tgtctcttta 4080
tgaggagttg tggcccgttg tcaggcaacg tggcgtggtg tgcactgtgt ttgctgacgc 4140
aacccccact ggttggggca ttgccaccac ctgtcagctc ctttccggga ctttcgcttt 4200
ccccctccct attgccacgg cggaactcat cgccgcctgc cttgcccgct gctggacagg 4260
ggctcggctg ttgggcactg acaattccgt ggtgttgtcg gggaagctga cgtcctttcc 4320
atggctgctc gcctgtgttg ccacctggat tctgcgcggg acgtccttct gctacgtccc 4380
ttcggccctc aatccagcgg accttccttc ccgcggcctg ctgccggctc tgcggcctct 4440
tccgcgtctt cgccttcgcc ctcagacgag tcggatctcc ctttgggccg cctccccgcc 4500
tggaattcga gctcggtacc tttaagacca atgacttaca aggcagctgt agatcttagc 4560
cactttttaa aagaaaaggg gggactggaa gggctaattc actcccaacg aagacaagat 4620
ctgctttttg cttgtactgg gtctctctgg ttagaccaga tctgagcctg ggagctctct 4680
ggctaactag ggaacccact gcttaagcct caataaagct tgccttgagt gcttcaagta 4740
gtgtgtgccc gtctgttgtg tgactctggt aactagagat ccctcagacc cttttagtca 4800
gtgtggaaaa tctctagcag tagtagttca tgtcatctta ttattcagta tttataactt 4860
gcaaagaaat gaatatcaga gagtgagagg aacttgttta ttgcagctta taatggttac 4920
aaataaagca atagcatcac aaatttcaca aataaagcat ttttttcact gcattctagt 4980
tgtggtttgt ccaaactcat caatgtatct tatcatgtct ggctctagct atcccgcccc 5040
taactccgcc catcccgccc ctaactccgc ccagttccgc ccattctccg ccccatggct 5100
gactaatttt ttttatttat gcagaggccg aggccgcctc ggcctctgag ctattccaga 5160
agtagtgagg aggctttttt ggaggcctag ggacgtaccc aattcgccct atagtgagtc 5220
gtattacgcg cgctcactgg ccgtcgtttt acaacgtcgt gactgggaaa accctggcgt 5280
tacccaactt aatcgccttg cagcacatcc ccctttcgcc agctggcgta atagcgaaga 5340
ggcccgcacc gatcgccctt cccaacagtt gcgcagcctg aatggcgaat gggacgcgcc 5400
ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga ccgctacact 5460
tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct tcctttctcg ccacgttcgc 5520
cggctttccc cgtcaagctc taaatcgggg gctcccttta gggttccgat ttagtgcttt 5580
acggcacctc gaccccaaaa aacttgatta gggtgatggt tcacgtagtg ggccatcgcc 5640
ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata gtggactctt 5700
gttccaaact ggaacaacac tcaaccctat ctcggtctat tcttttgatt tataagggat 5760
tttgccgatt tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat ttaacgcgaa 5820
ttttaacaaa atattaacgc ttacaattta ggtggcactt ttcggggaaa tgtgcgcgga 5880
acccctattt gtttattttt ctaaatacat tcaaatatgt atccgctcat gagacaataa 5940
ccctgataaa tgcttcaata atattgaaaa aggaagagta tgagtattca acatttccgt 6000
gtcgccctta ttcccttttt tgcggcattt tgccttcctg tttttgctca cccagaaacg 6060
ctggtgaaag taaaagatgc tgaagatcag ttgggtgcac gagtgggtta catcgaactg 6120
gatctcaaca gcggtaagat ccttgagagt tttcgccccg aagaacgttt tccaatgatg 6180
agcactttta aagttctgct atgtggcgcg gtattatccc gtattgacgc cgggcaagag 6240
caactcggtc gccgcataca ctattctcag aatgacttgg ttgagtactc accagtcaca 6300
gaaaagcatc ttacggatgg catgacagta agagaattat gcagtgctgc cataaccatg 6360
agtgataaca ctgcggccaa cttacttctg acaacgatcg gaggaccgaa ggagctaacc 6420
gcttttttgc acaacatggg ggatcatgta actcgccttg atcgttggga accggagctg 6480
aatgaagcca taccaaacga cgagcgtgac accacgatgc ctgtagcaat ggcaacaacg 6540
ttgcgcaaac tattaactgg cgaactactt actctagctt cccggcaaca attaatagac 6600
tggatggagg cggataaagt tgcaggacca cttctgcgct cggcccttcc ggctggctgg 6660
tttattgctg ataaatctgg agccggtgag cgtgggtctc gcggtatcat tgcagcactg 6720
gggccagatg gtaagccctc ccgtatcgta gttatctaca cgacggggag tcaggcaact 6780
atggatgaac gaaatagaca gatcgctgag ataggtgcct cactgattaa gcattggtaa 6840
ctgtcagacc aagtttactc atatatactt tagattgatt taaaacttca tttttaattt 6900
aaaaggatct aggtgaagat cctttttgat aatctcatga ccaaaatccc ttaacgtgag 6960
ttttcgttcc actgagcgtc agaccccgta gaaaagatca aaggatcttc ttgagatcct 7020
ttttttctgc gcgtaatctg ctgcttgcaa acaaaaaaac caccgctacc agcggtggtt 7080
tgtttgccgg atcaagagct accaactctt tttccgaagg taactggctt cagcagagcg 7140
cagataccaa atactgttct tctagtgtag ccgtagttag gccaccactt caagaactct 7200
gtagcaccgc ctacatacct cgctctgcta atcctgttac cagtggctgc tgccagtggc 7260
gataagtcgt gtcttaccgg gttggactca agacgatagt taccggataa ggcgcagcgg 7320
tcgggctgaa cggggggttc gtgcacacag cccagcttgg agcgaacgac ctacaccgaa 7380
ctgagatacc tacagcgtga gctatgagaa agcgccacgc ttcccgaagg gagaaaggcg 7440
gacaggtatc cggtaagcgg cagggtcgga acaggagagc gcacgaggga gcttccaggg 7500
ggaaacgcct ggtatcttta tagtcctgtc gggtttcgcc acctctgact tgagcgtcga 7560
tttttgtgat gctcgtcagg ggggcggagc ctatggaaaa acgccagcaa cgcggccttt 7620
ttacggttcc tggccttttg ctggcctttt gctcacatgt tctttcctgc gttatcccct 7680
gattctgtgg ataaccgtat taccgccttt gagtgagctg ataccgctcg ccgcagccga 7740
acgaccgagc gcagcgagtc agtgagcgag gaagcggaag agcgcccaat acgcaaaccg 7800
cctctccccg cgcgttggcc gattcattaa tgcagctggc acgacaggtt tcccgactgg 7860
aaagcgggca gtgagcgcaa cgcaattaat gtgagttagc tcactcatta ggcaccccag 7920
gctttacact ttatgcttcc ggctcgtatg ttgtgtggaa ttgtgagcgg ataacaattt 7980
cacacaggaa acagctatga ccatgattac gccaagcgcg caattaaccc tcactaaagg 8040
gaacaaaagc tggagctgca 8060
Claims (8)
1.包含胰岛样细胞团的制剂的制备方法,包括:
步骤1:将壳聚糖溶解于乙酸溶液,灭菌制得壳聚糖溶液;将胶原蛋白溶解于乙酸溶液,灭菌制得胶原蛋白溶液;
步骤2:将壳聚糖溶液与胶原蛋白溶液混合,以京尼平为交联剂进行交联制得降解材料;
步骤3:将降解材料与胰岛样细胞团混合,然后与含有乳化剂的植物油混合,加入固化剂于0~4℃搅拌2~5min,然后升温至35~40℃固化20~30min,制得所述制剂;
所述胰岛样细胞团由骨髓干细胞诱导分化制得;所述骨髓干细胞为表达融合蛋白Pdx-1-Linker-IGF-1的骨髓干细胞;所述诱导分化的培养基为含有30mmol/L葡萄糖和10mmol/LC肽的完全培养基。
2.根据权利要求1所述的制备方法,其特征在于,
所述壳聚糖为90%脱乙酰化的低分子量壳聚糖;
所述壳聚糖溶液中,乙酸的质量分数为1%,壳聚糖的质量分数为1%;
所述胶原蛋白为I型胶原蛋白;
所述胶原蛋白溶液中,乙酸的质量分数为1%,胶原蛋白的质量分数为3%。
3.根据权利要求1或2所述的制备方法,其特征在于,步骤2中所述壳聚糖溶液与胶原蛋白溶液的体积比为1:1。
4.根据权利要求1所述的制备方法,其特征在于,所述京尼平与壳聚糖溶液的质量-体积比为1g:100mL;所述交联的条件为室温反应1小时。
5.根据权利要求1所述的制备方法,其特征在于,步骤3中所述胰岛样细胞团在降解材料中的密度为1×106cell/mL。
6.根据权利要求1所述的制备方法,其特征在于,
所述乳化剂为Span80,在植物油中的质量分数为15%;
所述固化剂为京尼平,在植物油中的质量分数为1%。
7.由权利要求1~6任一项所述制备方法制得的包含胰岛样细胞团的制剂。
8.权利要求1~6任一项所述制备方法制得的包含胰岛样细胞团的制剂在制备治疗糖尿病的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811295075.1A CN109316464B (zh) | 2018-11-01 | 2018-11-01 | 包含胰岛样细胞团的制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811295075.1A CN109316464B (zh) | 2018-11-01 | 2018-11-01 | 包含胰岛样细胞团的制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109316464A CN109316464A (zh) | 2019-02-12 |
CN109316464B true CN109316464B (zh) | 2020-12-11 |
Family
ID=65260653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811295075.1A Active CN109316464B (zh) | 2018-11-01 | 2018-11-01 | 包含胰岛样细胞团的制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109316464B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113637630B (zh) * | 2020-05-11 | 2024-03-29 | 中国科学院分子细胞科学卓越创新中心 | 一种胰岛样细胞团及其制法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102240268A (zh) * | 2011-05-06 | 2011-11-16 | 河北科技大学 | 生物提取物京尼平交联壳聚糖包覆二苯乙烯类化合物的缓控释微球及其制备方法 |
CN103619328A (zh) * | 2011-03-29 | 2014-03-05 | β细胞公司 | 囊封治疗产品的方法及其用途 |
CN104257690A (zh) * | 2014-10-16 | 2015-01-07 | 奥思达干细胞有限公司 | 一种治疗糖尿病的干细胞制剂及其制备方法 |
CN104829851A (zh) * | 2015-04-24 | 2015-08-12 | 山东省科学院能源研究所 | 一种精确控制粒径的单分散明胶栓塞微球的制备方法 |
CN107753421A (zh) * | 2017-11-07 | 2018-03-06 | 天津大学 | 一种抗生物粘附聚电解质水凝胶及制备方法及应用 |
CN108542915A (zh) * | 2018-06-29 | 2018-09-18 | 胡葵葵 | 一种促进伤口愈合的药物及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9617562B2 (en) * | 2014-09-03 | 2017-04-11 | Jalaledin Ghanavi | Nonviral targeted nanoparticle system for gene transfer and drug delivery |
-
2018
- 2018-11-01 CN CN201811295075.1A patent/CN109316464B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103619328A (zh) * | 2011-03-29 | 2014-03-05 | β细胞公司 | 囊封治疗产品的方法及其用途 |
CN102240268A (zh) * | 2011-05-06 | 2011-11-16 | 河北科技大学 | 生物提取物京尼平交联壳聚糖包覆二苯乙烯类化合物的缓控释微球及其制备方法 |
CN104257690A (zh) * | 2014-10-16 | 2015-01-07 | 奥思达干细胞有限公司 | 一种治疗糖尿病的干细胞制剂及其制备方法 |
CN104829851A (zh) * | 2015-04-24 | 2015-08-12 | 山东省科学院能源研究所 | 一种精确控制粒径的单分散明胶栓塞微球的制备方法 |
CN107753421A (zh) * | 2017-11-07 | 2018-03-06 | 天津大学 | 一种抗生物粘附聚电解质水凝胶及制备方法及应用 |
CN108542915A (zh) * | 2018-06-29 | 2018-09-18 | 胡葵葵 | 一种促进伤口愈合的药物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
"Generation of Insulin-Producing Cells From PDX-1 Gene-Modified Human Mesenchymal stem cells;YANHUA LI;《J.cell.Physiol》;20070106;第36-44页 * |
诱导脐带间充质干细胞分化为胰岛素分泌细胞的方法探讨;王敬;《中国细胞生物学学报》;20170519;第39卷(第7期);第1-7页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109316464A (zh) | 2019-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5972596A (en) | Nucleic acid constructs containing HIV genes with mutated inhibitory/instability regions and methods of using same | |
KR20160023649A (ko) | 심근증을 치료하기 위한 유전자―치료 벡터 | |
KR20150025898A (ko) | 효모에 내산성을 부여하는 폴리펩티드, 그를 코딩하는 폴리뉴클레오티드, 그 양이 증가되어 있는 효모 세포, 상기 효모 세포를 이용한 산물의 생산 방법 및 내산성 효모 세포를 생산하는 방법 | |
CN109316464B (zh) | 包含胰岛样细胞团的制剂 | |
CN106566832B (zh) | 针对nfat3基因靶点的短发卡rna、重组载体及应用 | |
KR20220058489A (ko) | 인자 vii 요법을 위한 조성물, 디바이스 및 방법 | |
CN109161545B (zh) | 抑制鸡Sirt1基因表达的microRNA及其重组过表质粒以及LMH细胞系 | |
CN112961832A (zh) | 一种细胞株及其制备方法和用途 | |
CN111718932A (zh) | 一种新型的基因编辑动物生物反应器制备方法及应用 | |
CN111534578A (zh) | 一种高通量筛选真核生物细胞与农药互作的靶点基因的方法 | |
CN109336982B (zh) | 基因改造的干细胞及其应用 | |
CN108913692B (zh) | 特异性靶向SATB1基因的sgRNA及其在转录激活中的应用 | |
CN112245578B (zh) | 一种covid-19病毒预防性疫苗及其制备方法 | |
PT2385115E (pt) | Vetor de expressão para produção de proteína derivada de gene exógeno em grandes quantidades usando células animais e seu uso | |
US6387683B1 (en) | Recombinant yeast PDI and process for production thereof | |
CN111298129A (zh) | 二甲双胍介导核酸纳米材料自组装方法及采用该方法制备的纳米制剂和应用 | |
KR101831121B1 (ko) | 피리피로펜 생합성 유전자 클러스터 및 표지 유전자를 포함하는 핵산 구성체 | |
CN111534544A (zh) | 一种高通量筛选真核生物细胞与病毒互作靶点基因的方法 | |
CN109694878B (zh) | 一种基于原生质体的海带分子育种方法 | |
CN110964748B (zh) | 含线粒体靶向序列的载体及其构建方法和应用 | |
CN109913484A (zh) | 一种双向表达t载体以及其制备方法和应用 | |
US20040191869A1 (en) | Crystallography methods | |
US6623951B1 (en) | HBV vectors and cells for producing the same | |
CN111793639B (zh) | 一种利用与RNAi工程菌混配提高Bt杀虫活性的方法 | |
CN114085872A (zh) | 一种表达tva的小鼠模型的构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |